Fragment-based drug design (FBDD) receives more and more attention in the scientific community. The the fifth fragment-derived drug, sotorasib, received approval by the FDA for the treatment of non-small cell lung cancer this year. In this workshop we will discuss strategies around FBDD with recent med-chem use cases and how to utilize resources for lead optimization and idea generation. by thinking outside the box. Learn how to evolve a weak binder to a full-fledged drug candidate.
Participants can request a certificate of attendance.
